You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 196 No. 9, May 30, 1966 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Measles Vaccine Field Trials in Alaska

III. Two-Year Follow-up of Inactivated Vaccine Followed by Live, Attenuated Vaccine and of Immune Globulin With Live, Attenuated Vaccine

Jacob A. Brody, MD; E. Russell Alexander, MD; Mary Lou Hanson, RN

JAMA. 1966;196(9):757-760.


Abstract

Measles vaccine field trials in remote Alaskan Eskimo communities were followed up after two years. In one village, administration of inactivated measles virus vaccine had been followed in five to seven weeks by live, attenuated measles virus vaccine. In the second village, live vaccine had been given with measles immune globulin. Natural measles appeared in both villages after vaccination. Following exposure to natural measles, antibody rises were noted primarily among subjects with low titers. Titer rise was more frequent among those who received inactivated vaccine plus live vaccine. Two years after vaccination, and in spite of the booster effect of natural measles, titers among those who received inactivated vaccine plus live vaccine had fallen to low or undetectable levels in more than half of the recipients (51 of 85), suggesting that this combination may not produce lasting protection. Geometric mean titers were highest after natural measles, intermediate after live vaccine plus immune globulin, and lowest after inactivated vaccine plus live vaccine.



Author Affiliations

From the Epidemiology Section (Dr. Brody) and the Field Unit (Mrs. Hanson) of the Arctic Health Research Center, US Public Health Service, Anchorage, Alaska, and the Department of Preventive Medicine, University of Washington School of Medicine, Seattle (Dr. Alexander). Dr. Brody is now with the Epidemiology Branch, National Institute of Neurological Diseases and Blindness, Bethesda, Md. Dr. Alexander is Markle Scholar in Medical Science.


Footnotes

Parts I and II appeared in the issues of Aug 3 and Dec 14, 1965, respectively.

Reprint requests to 7550 Wisconsin Ave, Bethesda, Md 20014 (Dr. Brody).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

(Continued from page 156)
CLIN PEDIATR 1979;18:161-167.
 

Extensive Clinical Evaluations of a Highly Attenuated Live Measles Vaccine
JAMA 1967;199:26-30.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1966 American Medical Association. All Rights Reserved.